- /
- Supported exchanges
- / US
- / FDMT.NASDAQ
4D Molecular Therapeutics Inc (FDMT NASDAQ) stock market data APIs
4D Molecular Therapeutics Inc Financial Data Overview
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with 4D Molecular Therapeutics Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get 4D Molecular Therapeutics Inc data using free add-ons & libraries
Get 4D Molecular Therapeutics Inc Fundamental Data
4D Molecular Therapeutics Inc Fundamental data includes:
- Net Revenue: 92 008 K
- EBITDA: -188 890 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get 4D Molecular Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-08-13
- EPS/Forecast: -1.04
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
4D Molecular Therapeutics Inc News
New
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics, Inc. EMERYVILLE, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advanci...
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics, Inc. Completed enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027 4D-150 4FRONT-1 Phase 3 topline data expected in Q2 2027 Presented positive...
Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst calls
Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...
Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Surpass Estimates
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.25 per share a year ago. Thes...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.